Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials

Author:

Kelly Karen1,Infante Jeffrey R.2,Taylor Matthew H.3,Patel Manish R.4,Wong Deborah J.5,Iannotti Nicholas6,Mehnert Janice M.7ORCID,Loos Anja H.8,Koch Helga8,Speit Isabell8,Gulley James L.9

Affiliation:

1. Department of Internal Medicine; University of California-Davis Comprehensive Cancer Center; Sacramento California

2. Sarah Cannon Research Institute/Tennessee Oncology; PLLC; North Nashville Tennessee

3. Oregon Health and Science University Knight Cancer Institute; Portland Oregon

4. Sarah Cannon Research Institute/Florida Cancer Specialists; Sarasota Florida

5. Department of Medicine; University of California at Los Angeles; Los Angeles California

6. Hematology Oncology Associates of the Treasure Coast; Port St. Lucie Florida

7. Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School; Rutgers University; New Brunswick New Jersey

8. Merck KGaA; Darmstadt Germany

9. Genitourinary Malignancies Branch, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute; National Institutes of Health; Bethesda Maryland

Funder

Merck KGaA

Merck KGaA and Pfizer Inc

Pfizer

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3